1679-4974
1679-4974
S1679-49742022000201700
10.1590/s1679-49742022000200033
Australia
Netherlands
França
Australia
USA
Canada
Canadá
Líbano
USA
United Kingdom
Canadá
Denmark
Canadá
USA
Estados Unidos
Estados Unidos
United Kingdom
United Kingdom
United Kingdom
Canada
Canadá
Canadá
00
00
2022
00
00
2022
31
2
[
2018
555
7695
7695
175-82
]
[
2019
8
1
1
170
]
[
2018
16
1
1
233
]
[
PRISMA Group
2009
151
4
4
264-9
]
[
, PRISMA Group
2009
339
b2535
]
[
PRISMA Group
2009
6
7
7
]
[
PRISMA Group
2009
62
10
10
1006-12
]
[
PRISMA Group
2010
8
5
5
336-41
]
[
PRISMA Group
2009
3
3
3
]
[
PRISMA Group
2009
89
9
9
873-80
]
[
2007
4
3
3
]
[
2009
62
10
10
]
[
2009
339
b2700
]
[
2009
151
4
4
W65-94
]
[
2009
6
7
7
]
[
2009
6
4
4
354-91
]
[
2016
13
5
5
]
[
2013
8
12
12
]
[
2016
30
169-72
]
[
2019
115
46-54
]
[
2017
6
1
1
263
]
[
2015
4
1
1
5
]
[
2018
9
4
4
602-14
]
[
2019
8
1
1
163
]
[
2019
2nd ed
]
[
2019
4
^sSuppl 1
^sSuppl 1
Suppl 1
]
[
2020
368
l6890
]
[
2019
366
l4898
]
[
2016
355
i4919
]
[
ROBIS group
2016
69
225-34
]
[
2017
358
j4008
]
[
2017
87
4-13
]
[
2012
1
2
]
[
2012
1
1
]
[
2021
134
S0895-4356(21)00040-8
]
[
2018
94
8-18
]
[
2018
95
7-18
]
[
2020
118
60-8
]
[
2012
12
181
]
[
2019
19
1
1
25
]
[
2021
372
n160
]
[
2021
10
1
1
39
]
[
2019
]
[
2019
16
2
2
]
[
2019
3rd ed
]
[
Institute of Medicine (US). Committee on Standards for Systematic Reviews of Comparative Effectiveness Research
2011
]
[
PRISMA-P Group
2015
4
1
1
1
]
[
2015
350
g7647
]
[
2015
162
11
11
777-84
]
[
PRISMA-IPD Development Group
2015
313
16
16
1657-65
]
[
PRISMA Harms Group
2016
352
i157
]
[
the PRISMA-DTA Group
2018
319
4
4
388-96
]
[
2018
169
7
7
467-73
]
[
2013
10
]
[
2018
104
3
3
192-200
]
[
MUDS investigators
2018
9
1
1
2-12
]
[
2014
3
54
54
]
[
2022
]
[
2020
4
1
1
4-6
]
[
2015
13
221
]
[
2019
17
205
]
[
2019
5
11
11
1550-5
]
[
2017
6
1
1
185
]
[
2010
7
2
2
]
[
2010
8
24
]
[
2020
10
]
[
2014
348
g3804
]
[
IICARus Collaboration
2019
4
12
]
[
2019
9
5
5
]
[
2003
12
2
2
68-82
]
[
2012
9
10
10
]
[
2019
19
1
1
208
]